#concertai

[innonurse]

TeraRecon, an industry leader in advanced visualization and artificial intelligence (AI) for medical imaging, announced the launch of its next-generation Eureka Clinical AI platform. Designed to support the communication infrastructure and enable collaboration for the entire care team, the platform serves as an end-to-end clinical application integrating multiple AI algorithms and workflows.

[innonurse]

New clinical workflow software aims to solve timing challenges in neurovascular emergencies for the entire care team.

[mark-ai-code]

ConcertAI Closes $150 Million Funding Round to Accelerate Cancer Research with 1 Click

ConcertAI develops pharmaceutical data and AI analytics tools, and the list of partners is a familiar list of giants: Pfizer, Janssen, BMS

One of the most talked-about start-ups is ConcertAI, which was founded five years ago as Concerto HealthAI and has about 1,000 employees with offices in Cambridge, Philadelphia and Memphis, and Bangalore, India.

ConcertAI develops pharmaceutical data and AI analytics tools and has a list of familiar partners: Pfizer, Janssen, BMS (Bristol-Myers Squibb), etc. ConcertAI has also partnered with the FDA to study cancer. ConcertAI is part of the parent company SymphonyAI, which specializes in investing in, organizing, and incubating AI subsidiaries in various markets and fields.

ConcertAI recently announced the completion of a $150 million Series C funding round, valuing the company at $1.9 billion, making it one of the top companies of its kind. The investor is Sixth Street, a leading investment firm with $60 billion in assets under management and an increasing number of life science investments in recent years, as well as a leading investor in unicorns such as the NBA Spurs and Spotify, and Airbnb.

[aitechpark]

The expanded collaboration will fuel rapid insights into more effective treatments for patients utilizing ConcertAI's oncology Real-World Data and AI